Nightstar Therapeutics was an Oxford University spinout developing adeno-associated virus (AAV) gene therapies for inherited retinal diseases including choroideremia and retinitis pigmentosa. Founded in 2014, it completed a NASDAQ IPO in 2017 and was acquired by Biogen for approximately $800 million in June 2019.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJun 2017
Nov 2015
Jan 2015
Jan 2014
Create a free account to see which investors have funded this company.
Create Free Account
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
